Composition: Paracetamol BP 325 mg + Caffeine Anhydrous BP 30 mg; or Paracetamol BP 500 mg + Caffeine Anhydrous BP 30 mg per uncoated tablet/caplet.
Usage: Short-term relief of pain and headache, subject to locally approved indications.
Category: Analgesic Painkiller Drugs
Therapeutic class: Analgesic / Antipyretic + Caffeine Adjuvant
SKU: Paracetamol and Caffeine Anhydrous Tablets
Categories: Contract Manufacturer, Formulations Exporter India, Manufacturing Pharmaceutical Company India, Pharmaceutical Exporter India, Pharmaceutical Formulations India, Tablets Manufacturer, WHO GMP Certified Formulations
Paracetamol and Caffeine Anhydrous Tablets is listed for pharmaceutical business-to-business enquiries. Exact active ingredients, formulation, strength, pack configuration and manufacturer details should be confirmed against the product label and approved technical documentation before ordering.
Manufacturer: Healthy Life Pharma Pvt. Ltd. Exporter: Healthy Inc. Certifications, export status, manufacturing site, pack configurations and market authorizations should be verified against current documents.
Paracetamol is an analgesic and antipyretic. Caffeine is a stimulant that may enhance pain relief in certain combination formulations. The supplied product range includes uncoated tablets and a caplet containing these two ingredients. These products are not interchangeable with formulations containing ibuprofen, orphenadrine, phenylephrine or chlorpheniramine.
Any contract manufacturing, supply or export arrangement is subject to confirmation of the finished product specification, registration and applicable local regulations.
| Product variant | Declared composition per unit | Dosage form / standard |
|---|---|---|
| Paracetamol + Caffeine Tablets | Paracetamol BP 325 mg + Caffeine Anhydrous BP 30 mg | Uncoated tablet / BP |
| Paracetamol + Caffeine Caplet | Paracetamol BP 500 mg + Caffeine Anhydrous BP 30 mg | Uncoated caplet / BP |
| Paracetamol + Caffeine Tablets (additional supplied listing) | Paracetamol BP 325 mg + Caffeine BP 30 mg | Uncoated tablet / BP; caffeine form to verify |
| Paracetamol Tablets | Paracetamol IP 500 mg or 650 mg; Paracetamol BP 100 mg or 250 mg | Separate single-ingredient products |
| Parafen te | Ibuprofen IP 400 mg + Paracetamol IP 325 mg | Separate combination product |
| Paracetamol + Orphenadrine | Paracetamol 450 mg + Orphenadrine citrate 35 mg | Separate combination product |
| Cold-and-flu combination A | Paracetamol BP 325 mg + Caffeine BP 30 mg + Chlorpheniramine maleate BP 2 mg + Phenylephrine HCl BP 2.5 mg | Separate multi-ingredient product; Sunset Yellow listed |
| Cold-and-flu combination B | Paracetamol BP 325 mg + Caffeine BP 15 mg + Phenylephrine BP 2.5 mg + Chlorpheniramine BP 2 mg | Separate multi-ingredient product; Tartrazine listed |
Note: The supplied 500 mg + 65 mg formulation is mentioned in descriptive text only and is not supported by a corresponding composition declaration. Product-specific packaging and shelf life require confirmation.
For combination tablets, formulation development must demonstrate content uniformity for both paracetamol and the lower-dose caffeine component, acceptable mechanical strength, stability and dissolution performance. Blending, granulation, compression and packaging processes should be validated for the actual registered formula. No particular coating, humidity threshold, granulation process or pack material is confirmed by the supplied composition.
Appropriate controls may include identification, assay and content uniformity of both actives, dissolution or disintegration, impurities, stability and packaging integrity, using the applicable approved specifications and pharmacopoeial monographs. Numerical assay or dissolution acceptance limits should not be asserted without the relevant registered specification.
Paracetamol relieves pain and reduces fever; caffeine may act as an analgesic adjuvant in some headache and pain formulations. Product indications may include headache and other mild-to-moderate pain depending on approved local labeling. Paracetamol is not an NSAID and the caffeine combination is not automatically suitable for all migraine or severe-pain cases. Avoid unsupported claims of a fixed percentage improvement in efficacy.
Potential B2B documentation may include specifications, certificates of analysis, stability information and registration dossiers where available. WHO-GMP status, COPP/FSC, Star Export House designation and country-specific approvals must be checked before publication or customer commitments.
Q: What does anhydrous caffeine mean?
It refers to caffeine without water of crystallization; it does not itself establish greater clinical effectiveness.
Q: Is this the same as plain paracetamol?
No. These products contain caffeine as an additional active ingredient.
Q: Are the 325/30 mg and 500/30 mg strengths interchangeable?
No. Paracetamol content differs; use the exact labeled formulation and dosing advice.
Q: Is it the same as a branded product?
Brand equivalence cannot be assumed without matching the complete approved formulation and regulatory status.
Follow the specific approved label or prescriber's directions for the exact strength, age group and jurisdiction. Do not combine with other paracetamol-containing cold, flu or pain medicines. Total daily paracetamol exposure from all products matters; overdose can cause severe liver injury. Caffeine intake from beverages and other medicines should also be considered. Pediatric use depends on product-specific labeling.
Paracetamol: Serious liver damage can result from overdose; caution is needed with liver disease and heavy alcohol use. Rare serious skin reactions may occur. Caffeine: May cause insomnia, palpitations, anxiety, restlessness or tremor. Use caution in pregnancy, with heart rhythm disorders and in caffeine-sensitive individuals. Seek urgent medical care after suspected paracetamol overdose even if there are no immediate symptoms.
Store according to the approved product label, protected from inappropriate heat and moisture and out of children's reach. The exact temperature range, shelf life and packaging material must be confirmed from stability and labeling documentation.
Product information is intended for B2B reference and does not replace locally approved prescribing information or medical advice.